HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Viking Therapeutics (NASDAQ:VKTX) and maintains a $90 price target.
March 15, 2024 | 10:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Viking Therapeutics with a $90 price target.
The reiteration of a Buy rating and a high price target of $90 by a reputable analyst like Joseph Pantginis from HC Wainwright & Co. is a strong positive signal for Viking Therapeutics. This endorsement likely reflects confidence in the company's pipeline or market position, which could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100